Patents by Inventor Kai Gerlach

Kai Gerlach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE-IMIDAZOPYRIDINE DERIVATIVES
    Publication number: 20260199325
    Abstract: The present invention relates to compounds of formula(I), a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an association with the function of metabotropic glutamate receptor subtype 4 (mGluR4). A, Xa, Xb, Xc, Xd, A, R1 and R6 have meanings given in the description.
    Type: Application
    Filed: December 8, 2023
    Publication date: July 16, 2026
    Inventors: Roland PFAU, Georg DAHMANN, Kai GERLACH, Riccardo GIOVANNINI, Johann Faustus DU HOFFMANN, Christoph HOHN, Stefan JUST, Heiko SOMMER, Christian SPECKER
  • Dioxane derivatives
    Patent number: 12655136
    Abstract: The present invention relates to substituted dioxane derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of neuronal and non-neuronal conditions having an association with mGluR4 function and/or in the treatment of obesity by means of mGluR4 modulation.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: June 16, 2026
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roland Pfau, Georg Dahmann, Johann Faustus Du Hoffmann, Kai Gerlach, Riccardo Giovannini, Christoph Hohn, Stefan Just, Thorsten Lehmann, Anton Pekcec, Julia Schlichtiger, Heiko Sommer, Christian Specker
  • NOVEL NAV 1.1 POTENTIATORS
    Publication number: 20260116870
    Abstract: The present invention relates to 2,3-dihydro-1H-isoindol-1-one derivatives, their pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the voltage-gated sodium channel Nav1.1.
    Type: Application
    Filed: October 27, 2025
    Publication date: April 30, 2026
    Inventors: Kai GERLACH, Sarah Margaret MAJOR, Konstantinos RAMPALAKOS
  • Substituted pyrazine-carboxamide derivatives
    Patent number: 12421218
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an association with the function of metabotropic glutamate receptor subtype 4 (mGluR4). A, R1, R2, R3, R4, R5 and R6 have meanings given in the description.
    Type: Grant
    Filed: August 14, 2024
    Date of Patent: September 23, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roland Pfau, Georg Dahmann, Johann Faustus Du Hoffmann, Kai Gerlach, Riccardo Giovaninni, Christoph Hohn, Stefan Just, Thorsten Lehmann, Anton Pekcec, Stefan Peters, Julia Schlichtiger, Heiko Sommer, Christian Specker, Dieter Wiedenmayer
  • Substituted xanthines as modulators of TRPC5 activity
    Patent number: 12291532
    Abstract: The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: May 6, 2025
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • CCR2 receptor antagonists and uses thereof
    Patent number: 12209094
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: January 28, 2025
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVES
    Publication number: 20240417394
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an association with the function of metabotropic glutamate receptor subtype 4 (mGluR4). A, R1, R2, R3, R4, R5 and R6 have meanings given in the description.
    Type: Application
    Filed: August 14, 2024
    Publication date: December 19, 2024
    Inventors: Roland PFAU, Georg DAHMANN, Johann Faustus DU HOFFMANN, Kai GERLACH, Riccardo GIOVANINNI, Christoph HOHN, Stefan JUST, Thorsten LEHMANN, Anton PEKCEC, Stefan PETERS, Julia SCHLICHTIGER, Heiko SOMMER, Christian SPECKER, Dieter WIEDENMAYER
  • 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
    Patent number: 12115157
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: October 15, 2024
    Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • Modulators of complex I
    Patent number: 12071403
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Grant
    Filed: September 7, 2023
    Date of Patent: August 27, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Christian Eickmeier, Jan Magnus Kriegl, Lothar Kussmaul, Klaus Rudolf, Bernhard Schmid
  • NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVES
    Publication number: 20240182453
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an association with the function of metabotropic glutamate receptor subtype 4 (mGluR4). A, R1, R2, R3, R4, R5 and R6 have meanings given in the description.
    Type: Application
    Filed: October 27, 2023
    Publication date: June 6, 2024
    Inventors: Roland PFAU, Georg DAHMANN, Johann Faustus DU HOFFMANN, Kai GERLACH, Riccardo GIOVANINNI, Christoph HOHN, Stefan JUST, Thorsten LEHMANN, Anton PEKCEC, Stefan PETERS, Julia SCHLICHTIGER, Heiko SOMMER, Christian SPECKER, Dieter WIEDENMAYER
  • NOVEL DIOXANE DERIVATIVES
    Publication number: 20240174652
    Abstract: The present invention relates to substituted dioxane derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of neuronal and non-neuronal conditions having an association with mGluR4 function and/or in the treatment of obesity by means of mGluR4 modulation.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 30, 2024
    Inventors: Roland PFAU, Georg DAHMANN, Johann Faustus DU HOFFMANN, Kai GERLACH, Riccardo GIOVANNINI, Christoph HOHN, Stefan JUST, Thorsten LEHMANN, Anton PEKCEC, Julia SCHLICHTIGER, Heiko SOMMER, Christian SPECKER
  • MODULATORS OF COMPLEX I
    Publication number: 20240150285
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Application
    Filed: September 7, 2023
    Publication date: May 9, 2024
    Inventors: Kai GERLACH, Christian EICKMEIER, Jan Magnus KRIEGL, Lothar KUSSMAUL, Klaus RUDOLF, Bernhard SCHMID
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20240109909
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 4, 2024
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Modulators of complex I
    Patent number: 11795147
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Christian Eickmeier, Jan Magnus Kriegl, Lothar Kussmaul, Klaus Rudolf, Bernhard Schmid
  • Substituted 3-phenoxyazetidin-1-yl-pyrazines
    Patent number: 11780827
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: October 10, 2023
    Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11731981
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: August 22, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT
    Publication number: 20230131465
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 27, 2023
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES
    Publication number: 20220356172
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 10, 2022
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • NOVEL SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20220177479
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 9, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • Triazolo pyridines as modulators of gamma-secretase
    Patent number: 11339161
    Abstract: The present invention relates to triazolo pyridines of formula (II) and their use as modulators of #-secretase. In particular, the present invention relates to compounds which interfere with #-secretase and/or its substrate and therefore modulate the formation of A? peptides. Accordingly these compounds can be used for the treatment of A?-related pathologies, e.g. Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 24, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Niklas Heine, Christian Eickmeier, Kai Gerlach, Ulrike Gross